Genzyme Plans Phase III With Oral Gaucher Drug Next Year
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech provides an update on key projects during R&D day for investors.
You may also be interested in...
Pending Approvals Hold Major Implications For Myozyme Growth
Genzyme reports increasing sales for Pompe disease drug, but upcoming EU and FDA decisions could spur or stifle product’s growth.
Pending Approvals Hold Major Implications For Myozyme Growth
Genzyme reports increasing sales for Pompe disease drug, but upcoming EU and FDA decisions could spur or stifle product’s growth.
PTC Taps Genzyme’s Global Reach, Pocketbook In Ultra-orphan Licensing Deal
PTC124 offers new approach for treating lysosomal storage disorders central to Genzyme’s success, as well as other genetic diseases.